307 related articles for article (PubMed ID: 37272701)
21. CDK9: A key player in cancer and other diseases.
Franco LC; Morales F; Boffo S; Giordano A
J Cell Biochem; 2018 Feb; 119(2):1273-1284. PubMed ID: 28722178
[TBL] [Abstract][Full Text] [Related]
22. Development of temperature-sensitive mutants of the Drosophila melanogaster P-TEFb (Cyclin T/CDK9) heterodimer using yeast two-hybrid screening.
Kim S; Min IM; Ren S; Spector A; Jin MM; Lis JT
Biochem Biophys Res Commun; 2013 Apr; 433(2):243-8. PubMed ID: 23500466
[TBL] [Abstract][Full Text] [Related]
23. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
24. The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition.
Albert TK; Antrecht C; Kremmer E; Meisterernst M
PLoS One; 2016; 11(1):e0146648. PubMed ID: 26745862
[TBL] [Abstract][Full Text] [Related]
25. Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway.
Ramakrishnan R; Rice AP
J Cell Physiol; 2012 Feb; 227(2):609-17. PubMed ID: 21448926
[TBL] [Abstract][Full Text] [Related]
26. CDK9 a potential target for drug development.
Canduri F; Perez PC; Caceres RA; de Azevedo WF
Med Chem; 2008 May; 4(3):210-8. PubMed ID: 18473913
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
28. Transcription Elongation Factor P-TEFb Is Involved in IL-17F Signaling in Airway Smooth Muscle Cells.
Nakajima M; Kawaguchi M; Matsuyama M; Ota K; Fujita J; Matsukura S; Huang SK; Morishima Y; Ishii Y; Satoh H; Sakamoto T; Hizawa N
Int Arch Allergy Immunol; 2018; 176(2):83-90. PubMed ID: 29649811
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms controlling CDK9 activity.
Marshall RM; Grana X
Front Biosci; 2006 Sep; 11():2598-613. PubMed ID: 16720337
[TBL] [Abstract][Full Text] [Related]
30. Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders.
Koirala M; DiPaola M
Curr Issues Mol Biol; 2024 Feb; 46(3):1713-1730. PubMed ID: 38534727
[TBL] [Abstract][Full Text] [Related]
31. A patent review of selective CDK9 inhibitors in treating cancer.
Wu T; Wu X; Xu Y; Chen R; Wang J; Li Z; Bian J
Expert Opin Ther Pat; 2023 Apr; 33(4):309-322. PubMed ID: 37128897
[TBL] [Abstract][Full Text] [Related]
32. Separate domains of fission yeast Cdk9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxyl-terminal domain substrate recognition.
St Amour CV; Sansó M; Bösken CA; Lee KM; Larochelle S; Zhang C; Shokat KM; Geyer M; Fisher RP
Mol Cell Biol; 2012 Jul; 32(13):2372-83. PubMed ID: 22508988
[TBL] [Abstract][Full Text] [Related]
33. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription.
O'Keeffe B; Fong Y; Chen D; Zhou S; Zhou Q
J Biol Chem; 2000 Jan; 275(1):279-87. PubMed ID: 10617616
[TBL] [Abstract][Full Text] [Related]
34. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
[TBL] [Abstract][Full Text] [Related]
35. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
36. A positive feedback loop links opposing functions of P-TEFb/Cdk9 and histone H2B ubiquitylation to regulate transcript elongation in fission yeast.
Sansó M; Lee KM; Viladevall L; Jacques PÉ; Pagé V; Nagy S; Racine A; St Amour CV; Zhang C; Shokat KM; Schwer B; Robert F; Fisher RP; Tanny JC
PLoS Genet; 2012; 8(8):e1002822. PubMed ID: 22876190
[TBL] [Abstract][Full Text] [Related]
37. Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription.
Sabò A; Lusic M; Cereseto A; Giacca M
Mol Cell Biol; 2008 Apr; 28(7):2201-12. PubMed ID: 18250157
[TBL] [Abstract][Full Text] [Related]
38. Disrupting the Cdk9/Cyclin T1 heterodimer of 7SK snRNP for the Brd4 and AFF1/4 guided reconstitution of active P-TEFb.
Zhou K; Zhuang S; Liu F; Chen Y; Li Y; Wang S; Li Y; Wen H; Lin X; Wang J; Huang Y; He C; Xu N; Li Z; Xu L; Zhang Z; Chen LF; Chen R; Liu M
Nucleic Acids Res; 2022 Jan; 50(2):750-762. PubMed ID: 34935961
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel CDK9 inhibitor targeting the intramolecular hidden cavity of CDK9 induced by Tat binding.
Asamitsu K; Hirokawa T; Okamoto T
PLoS One; 2022; 17(11):e0277024. PubMed ID: 36378653
[TBL] [Abstract][Full Text] [Related]
40. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.
Zhang Y; Shan L; Tang W; Ge Y; Li C; Zhang J
J Med Chem; 2024 Apr; 67(7):5185-5215. PubMed ID: 38564299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
